CGEM logo

Cullinan Therapeutics Inc. (CGEM)

$9.28

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CGEM

Market cap

$602141570

EPS

-3.08

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

-0.024805

Price on CGEM

Previous close

$9.50

Today's open

$9.45

Day's range

$8.47 - $9.45

52 week range

$8.23 - $23.19

Profile about CGEM

CEO

Nadim Ahmed

Employees

109

Headquarters

Cambridge, MA

Exchange

Nasdaq Global Select

Shares outstanding

64920924

Issue type

Common Stock

CGEM industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CGEM

Cullinan Therapeutics, Inc. (CGEM) Presents at UBS Global Biopharma Conference 2026 Transcript

Cullinan Therapeutics, Inc. ( CGEM ) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST Company Participants Nadim Ahmed - President, CEO & Director Jeffrey Jones - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right. Welcome back, everyone.

news source

Seeking Alpha • Nov 17, 2026

news preview

New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Submission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLC Submission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLC

news source

GlobeNewsWire • Nov 12, 2026

news preview

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren's disease will be shared in December Velinotamig (BCMA TCE) data presented at ACR Convergence 2026; global Phase 1/2 study in autoimmune cytopenias initiated CLN-049 (FLT3 TCE) potentially registrational Phase 2 study in R/R AML underway; updated data from the Phase 1 dose escalation study will be presented at the 2026 ASH Annual Meeting Zipalertinib NDA submission for first-line combination therapy in EGFR ex20ins NSCLC initiated under U.S. FDA Real-Time Oncology Review program; completion expected in November Cash and investments of $313.8 million as of September 30, 2026; runway into 2029 CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that members of its management team will participate in fireside chats at the following upcoming investor conferences:

news source

GlobeNewsWire • Nov 9, 2026

news preview

Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026

Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses

news source

GlobeNewsWire • Nov 8, 2026

news preview

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that two of its T cell engager programs, CLN-049, a FLT3xCD3 T cell engager, and velinotamig (CLN-803), a BCMAxCD3 T cell engager, will be featured across four poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15 in New Orleans, Louisiana.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Oct 29, 2026

news preview

3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead

Small caps led the market into spring and have been handing it back ever since. The Russell 2000 has cooled, defense and drone names sit well off their highs, and the riskier corners of biotech and critical minerals have been marked down right alongside them.

news source

MarketBeat • Oct 28, 2026

news preview

Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA

Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA

news source

GlobeNewsWire • Oct 27, 2026

news preview

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations or other uncommon EGFR mutations and active central nervous system (CNS) metastases. The data will be.

news source

Business Wire • Oct 19, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Cullinan Therapeutics Inc.

Open an M1 investment account to buy and sell Cullinan Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CGEM on M1